If a patient is asking about GLP-1/GIP medicines, direct them to a conversation with their prescriber and share neutral background reading on those medicines from peer-reviewed journals
The health risks are too high to be negligent
Never pour solutions down the drain
In WT and obese animals, AOD9604 reduces fat mass, increases 3-AR expression, enhances lipolysis, and stimulates energy expenditure and fat oxidation
Mistakes in either direction, too much AOD 9604 or too rapid tirzepatide escalation, create unnecessary side effects without additional benefit
It's not uncommon for early-stage studies to face inconsistencies, and often, the root cause traces back to inaccurate dosage calculations